Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study.
Advanced glycation end-products
Biomarker
Major adverse cardiovascular events
Mortality
Type 2 diabetes
sRAGE
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
06 06 2022
06 06 2022
Historique:
received:
28
04
2022
accepted:
26
05
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
Advanced glycation end-products (AGEs) and their interaction with the receptor for advanced glycation end-products (RAGE) play a pivotal role in the development and progression of type 2 diabetes. In this retrospective cohort study, we explored the association of circulating levels of soluble RAGE (sRAGE) isoforms, i.e., endogenous secretory esRAGE and cleaved cRAGE, AGEs and their respective ratios with 15-year all-cause mortality in type 2 diabetes. Baseline AGEs and sRAGE isoforms concentration were measured by ELISA in 362 patients with type 2 diabetes and in 125 age- and gender-matched healthy control subjects (CTR). Independent predictors of mortality were determined using Cox proportional-hazards models and used to build and validate a nomogram for all-cause mortality prediction in type 2 diabetes. AGEs, total sRAGE, cRAGE and the AGEs/sRAGE and AGEs/esRAGE ratios were significantly increased in patients with type 2 diabetes compared to CTR (p < 0.001). In CTR subjects, but not in type 2 diabetes patients, a significant negative correlation between cRAGE and age was confirmed (p = 0.003), whereas the AGEs/sRAGE (p = 0.032) and AGEs/cRAGE (p = 0.006) ratios were positively associated with age. At an average follow-up of 15 years (4,982 person-years), 130 deaths were observed. The increase in the AGEs/cRAGE ratio was accompanied by a higher risk of all-cause mortality in patients with type 2 diabetes (HR per each SD increment = 1.30, 95% CI 1.15-1.47; p < 0.001). Moreover, sRAGE was associated with the development of major adverse cardiovascular events (MACE) in type 2 diabetes patients without previous MACE (OR for each SD increase: 1.48, 95% CI 1.11-1.89). A nomogram based on age, sex, HbA1c, systolic blood pressure, and the AGEs/cRAGE ratio was built to predict 5-, 10- and 15-year survival in type 2 diabetes. Patients were categorized into quartiles of the monogram scores and Kaplan-Meier survival curves confirmed the prognostic accuracy of the model (log-rank p = 6.5 × 10 The ratio between AGEs and the cRAGE isoform is predictive of 15-year survival in patients with type 2 diabetes. Our data support the assessment of circulating AGEs and soluble RAGE isoforms in patients with type 2 diabetes as predictors of MACE and all-cause mortality.
Sections du résumé
BACKGROUND
Advanced glycation end-products (AGEs) and their interaction with the receptor for advanced glycation end-products (RAGE) play a pivotal role in the development and progression of type 2 diabetes. In this retrospective cohort study, we explored the association of circulating levels of soluble RAGE (sRAGE) isoforms, i.e., endogenous secretory esRAGE and cleaved cRAGE, AGEs and their respective ratios with 15-year all-cause mortality in type 2 diabetes.
METHODS
Baseline AGEs and sRAGE isoforms concentration were measured by ELISA in 362 patients with type 2 diabetes and in 125 age- and gender-matched healthy control subjects (CTR). Independent predictors of mortality were determined using Cox proportional-hazards models and used to build and validate a nomogram for all-cause mortality prediction in type 2 diabetes.
RESULTS
AGEs, total sRAGE, cRAGE and the AGEs/sRAGE and AGEs/esRAGE ratios were significantly increased in patients with type 2 diabetes compared to CTR (p < 0.001). In CTR subjects, but not in type 2 diabetes patients, a significant negative correlation between cRAGE and age was confirmed (p = 0.003), whereas the AGEs/sRAGE (p = 0.032) and AGEs/cRAGE (p = 0.006) ratios were positively associated with age. At an average follow-up of 15 years (4,982 person-years), 130 deaths were observed. The increase in the AGEs/cRAGE ratio was accompanied by a higher risk of all-cause mortality in patients with type 2 diabetes (HR per each SD increment = 1.30, 95% CI 1.15-1.47; p < 0.001). Moreover, sRAGE was associated with the development of major adverse cardiovascular events (MACE) in type 2 diabetes patients without previous MACE (OR for each SD increase: 1.48, 95% CI 1.11-1.89). A nomogram based on age, sex, HbA1c, systolic blood pressure, and the AGEs/cRAGE ratio was built to predict 5-, 10- and 15-year survival in type 2 diabetes. Patients were categorized into quartiles of the monogram scores and Kaplan-Meier survival curves confirmed the prognostic accuracy of the model (log-rank p = 6.5 × 10
CONCLUSIONS
The ratio between AGEs and the cRAGE isoform is predictive of 15-year survival in patients with type 2 diabetes. Our data support the assessment of circulating AGEs and soluble RAGE isoforms in patients with type 2 diabetes as predictors of MACE and all-cause mortality.
Identifiants
pubmed: 35668468
doi: 10.1186/s12933-022-01535-3
pii: 10.1186/s12933-022-01535-3
pmc: PMC9169316
doi:
Substances chimiques
Biomarkers
0
Glycation End Products, Advanced
0
Protein Isoforms
0
Receptor for Advanced Glycation End Products
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
95Informations de copyright
© 2022. The Author(s).
Références
J Leukoc Biol. 2021 Mar;109(3):605-619
pubmed: 32678947
Nat Med. 1998 Sep;4(9):1025-31
pubmed: 9734395
Am J Physiol Endocrinol Metab. 2017 Dec 1;313(6):E631-E640
pubmed: 28811295
Metabolism. 2018 Jun;83:120-127
pubmed: 29409822
Exp Gerontol. 2015 Aug;68:71-5
pubmed: 25536383
PLoS One. 2015 Mar 20;10(3):e0119983
pubmed: 25793407
Aging (Albany NY). 2019 Mar 23;11(6):1648-1663
pubmed: 30903794
Am J Kidney Dis. 2009 Jan;53(1):51-8
pubmed: 18789567
Front Endocrinol (Lausanne). 2021 Aug 26;12:726182
pubmed: 34512554
J Leukoc Biol. 2007 Aug;82(2):204-12
pubmed: 17513693
Circulation. 2003 May 6;107(17):2238-43
pubmed: 12719284
Endocrinology. 2020 Jan 1;161(1):
pubmed: 31638645
Exp Mol Med. 2019 Sep 27;51(9):1-15
pubmed: 31562296
Genet Mol Res. 2016 Jul 14;15(2):
pubmed: 27421025
Trends Biochem Sci. 2011 Dec;36(12):625-32
pubmed: 22019011
Sci Rep. 2016 Mar 03;6:22450
pubmed: 26936329
J Investig Med. 2011 Dec;59(8):1233-8
pubmed: 21941211
Front Cardiovasc Med. 2020 Mar 10;7:37
pubmed: 32211423
Diabetologia. 2010 Nov;53(11):2442-51
pubmed: 20631980
Diabet Med. 2013 Jun;30(6):702-9
pubmed: 23432638
Nutr Metab Cardiovasc Dis. 2022 May;32(5):1083-1092
pubmed: 35260315
PLoS One. 2014 Jan 27;9(1):e86903
pubmed: 24475194
J Clin Endocrinol Metab. 2014 Feb;99(2):587-93
pubmed: 24276448
Cardiovasc Diabetol. 2021 Jun 27;20(1):110
pubmed: 34176469
Molecules. 2020 Nov 10;25(22):
pubmed: 33182705
Age Ageing. 2019 Sep 1;48(5):696-702
pubmed: 31211360
Mech Ageing Dev. 2015 Jan;145:18-25
pubmed: 25681682
Exp Clin Endocrinol Diabetes. 2012 May;120(5):277-81
pubmed: 22549347
Diabetes. 2010 Aug;59(8):2027-32
pubmed: 20522598
Diabetes. 2011 Sep;60(9):2379-85
pubmed: 21771973
Diabetes Metab Syndr. 2022 Mar;16(3):102441
pubmed: 35247657
Mol Cell Biochem. 2016 Dec;423(1-2):105-114
pubmed: 27714575
Cardiovasc Diabetol. 2007 Mar 07;6:9
pubmed: 17343760
PLoS One. 2015 Aug 06;10(8):e0128881
pubmed: 26248341
Geroscience. 2021 Jun;43(3):1317-1329
pubmed: 33599920
Redox Biol. 2021 Jun;42:101958
pubmed: 33839083
Mol Med. 2007 Mar-Apr;13(3-4):185-9
pubmed: 17592553
PLoS One. 2015 Sep 01;10(9):e0137330
pubmed: 26325204
Atherosclerosis. 2017 Nov;266:234-239
pubmed: 28864204
Clin Chem. 2005 Sep;51(9):1749-50
pubmed: 16120960
Atherosclerosis. 2009 Oct;206(2):540-5
pubmed: 19368923
Int J Cardiol. 2013 Oct 3;168(3):1788-94
pubmed: 23722052
J Clin Endocrinol Metab. 2016 Apr;101(4):1701-9
pubmed: 26885882
Can J Diabetes. 2021 Oct;45(7):634-640
pubmed: 33773934
Eur J Nutr. 2017 Dec;56(8):2557-2564
pubmed: 27522371
Biochim Biophys Acta Gen Subj. 2017 Feb;1861(2):354-364
pubmed: 27913191
Diabetes Care. 2010 Jan;33 Suppl 1:S62-9
pubmed: 20042775
Biomark Med. 2021 Aug;15(11):785-796
pubmed: 34236256
Diabetologia. 2011 Oct;54(10):2669-77
pubmed: 21607631
Diabetologia. 2009 Nov;52(11):2251-63
pubmed: 19636529
Redox Biol. 2014 Jan 09;2:411-29
pubmed: 24624331
Cells. 2019 Aug 16;8(8):
pubmed: 31426413
Diabet Med. 2018 Apr 23;:
pubmed: 29687658
Atherosclerosis. 2013 Apr;227(2):425-8
pubmed: 23384720
J Diabetes Metab Disord. 2020 May 12;19(1):515-521
pubmed: 32550204
Diabetes Metab Syndr. 2019 Jul - Aug;13(4):2457-2461
pubmed: 31405660
Stat Med. 2011 Jan 15;30(1):11-21
pubmed: 21204120
Diabetes. 2014 Jun;63(6):1948-65
pubmed: 24520121
Lancet Diabetes Endocrinol. 2017 Oct;5(10):788-798
pubmed: 28803840
Int J Biol Sci. 2021 Jun 11;17(10):2399-2416
pubmed: 34326683
Cardiovasc Diabetol. 2021 Oct 16;20(1):208
pubmed: 34656131
FASEB J. 2008 Oct;22(10):3716-27
pubmed: 18603587
Am J Physiol Endocrinol Metab. 2001 May;280(5):E685-94
pubmed: 11287350
Diabetes Care. 2015 Oct;38(10):1891-7
pubmed: 26253728
Diabetes Metab Res Rev. 2014 Nov;30(8):679-85
pubmed: 24449227